Study links hypoxia pathway dysregulation to glioblastoma treatment
Researchers found that hypoxia‐responsive pathways, anchored by the master regulator HIF1A, are under markedly stronger transcriptional control in female glioblastoma than in male glioblastoma or in slower‑growing low‑grade gliomas.
A study by researchers at Johns Hopkins University and Harvard T.H. Chan School of Public Health showed that female glioblastoma patients have a distinct rewiring of hypoxia‐responsive gene regulation, with stronger transcriptional control of HIF1A‐driven pathways. These changes link hypoxia to metabolic, immune and extracellular matrix programs, offering a mechanistic explanation for sex differences in treatment resistance and suggesting that drugs targeting HIF1A could be explored as sex‑specific therapy for women with glioblastoma.
The findings highlight that the biological mechanisms driving glioblastoma treatment resistance differ between men and women, indicating that drug strategies may need to be sex‑specific.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.